Table 1. Overall characteristics of allogeneic hematopoietic stem cell transplantation recipients with or without tuberculosis.
| Characteristics | TB (n = 21) | No TB (n = 824) | P |
|---|---|---|---|
| Age (median, range) | 41 (18–60) | 40 (18–72) | 0.960 |
| Sex (M,%) | 10 (47.6) | 473 (57.4) | 0.371 |
| Transplantation year (%) | 0.280 | ||
| • Jan. 2004-Mar. 2009 | 16 (76.2) | 534 (64.8) | |
| • Apr. 2009-Mar. 2011 | 5 (23.8) | 290 (35.2) | |
| Diagnosis (%) | 0.569 | ||
| • AML | 12 (57.1) | 399 (48.4) | |
| • ALL | 4 (19.4) | 227 (27.5) | |
| • MDS | 4 (19.4) | 118 (14.3) | |
| • CML | 0 (0) | 53 (6.4) | |
| • MM | 1 (4.8) | 27 (3.3) | |
| Donor type (%) | 0.870 | ||
| • Matched sibling | 12 (57.1) | 456 (55.3) | |
| • Alternativea | 9 (42.9) | 368 (44.7) | |
| Stem cell source (%) | 0.163 | ||
| • BM | 11 (52.4) | 388 (47.1) | |
| • PB | 8 (38.1) | 406 (49.3) | |
| • BM+PB | 2 (9.5) | 19 (2.3) | |
| • Cord blood | 0 (0) | 11 (1.3) | |
| Conditioning regimen (%) | 0.918 | ||
| • TBI based | 15 (71.4) | 597 (72.5) | |
| • no-TBI based | 6 (28.6) | 227 (27.5) | |
| ATG given as conditioning (%) | 0.662 | ||
| • Yes | 5 (23.8) | 232 (28.2) | |
| • No | 16 (76.2) | 592 (71.8) | |
| Conditioning intensity (%) | 0.779 | ||
| • MAC | 13 (61.9) | 485 (58.9) | |
| • RIC | 8 (38.1) | 339 (41.1) | |
| GVHD prophylaxis (%) | 0.693 | ||
| • CS based | 12 (57.1) | 435 (52.8) | |
| • FK based | 9 (42.9) | 389 (47.2) | |
| Acute GVHD (%) | 0.983 | ||
| • Grade 0-I | 13 (61.9) | 512 (62.1) | |
| • Grade II-IV | 8 (38.1) | 312 (37.9) | |
| Chronic GVHD (%) | 0.003 | ||
| • None + Limited | 8 (38.1) | 569 (69.1) | |
| • Extensive | 13 (61.9) | 255 (30.9) | |
| Relapse | 0.597 | ||
| • Yes | 4 (19.0) | 198 (24.0) | |
| • No | 17 (81.0) | 626 (76.0) | |
| Follow-up duration, median days (range) | 0.268 | ||
| • Patients who died | 343 (121–799) | 259 (2-2959) | |
| • Patients alive at last follow-up | 2353 (258–3217) | 2037 (108–3916) |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ATG, anti-thymocyte globulin; BM, bone marrow stem cell; CML, chronic myelogenous leukemia; CS, cyclosporine; FK, tacrolimus; GVHD, graft-versus-host disease; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; PB, peripheral blood stem cell; RIC, reduced intensity conditioning; TB, tuberculosis; TBI, total body irradiation.
a alternative donor included unrelated donors and mismatched relatives.